Clinical trials: Influenza Human
Influenza, Common Cold
A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
The study is designed to investigate whether paracetamol from a hot remedy reaches the plasma faster than standard paracetamol tablets.
- Trial name
- NCT01332578
- Testing
- Paracetamol, Phenylephrine, Ascorbic Acid
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza Vaccines
A Randomized Study to Compare the Safety and Immunogenicity of Fluviral® Made With New Versus Aged Bulk
Vaccination is currently the most effective means of controlling influenza and preventing its complications and mortality in persons at risk.
- Trial name
- NCT00586469
- Testing
- Fluviral
- Where
- 8 sites in Canada
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of the Protective Effect of an Injectable Influenza Vaccine Against Influenza Illness in Adults Under 50 y.o.
The goal of this study is to determine whether Fluviral, an inactivated, injectable trivalent influenza vaccine (flu shot) is effective in preventing respiratory illnesses that are severe enough to limit normal daily activities…
- Trial name
- NCT00216242
- Testing
- Influenza virus vaccine (Fluviral)
- Where
- 43 sites in United States
- Volunteers
- 7,400 people, healthy volunteers welcome
- Sponsor
- ID Biomedical Corporation, Quebec
Influenza Prevention
Study to Assess the Prophylactic Efficacy and Safety of Sebaloxavir Marboxil Tablets/Oral Suspension for Influenza Prevention in Household Contacts Aged ≥2 Years.
This study is a randomized, double-blind, placebo-controlled phase III clinical trial. The trial participants include index participants (IP) and household contacts (HHC).
- Trial name
- NCT07730346
- Testing
- Sebaloxavir marboxil
- Where
- China
- Volunteers
- 858 people, healthy volunteers welcome
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Influenza
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 18 years and over
- Trial name
- NCT00329966
- Testing
- Surface Antigen, Inactivated, Influenza (form.2006-07)
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Novartis
Enhancement of Protective Antibody Response After Probiotic Consumption
Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults
the aim of the study is to get evidence for an enhancement of immune status in subjects after probiotics mixture consumption ( lactobacillus gasseri PA 16/8, Bifidobacterrium longum SP 07/3, Bifidobacterium bifidum MF 20/5) based…
- Trial name
- PROBIMMUNE (NCT01652066)
- Testing
- Mixture of probiotics, Mixture of probitiocs
- Where
- France
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Merck Medication Familiale
Influenza
Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine
The purpose of this study is to compare immunogenicity and safety of ASP7374 (cell-culture derived influenza vaccine) with those of approved egg-derived trivalent inactivated vaccine (TIV) in elderly subjects.
- Trial name
- NCT01767896
- Testing
- ASP7374, approved egg-derived TIV
- Where
- 3 sites in Japan
- Volunteers
- 1,020 people, healthy volunteers welcome
- Sponsor
- UMN Pharma Inc.
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
- Trial name
- NCT01999842
- Testing
- Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A
- Where
- 8 sites in United States, Canada
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications
The study is designed to evaluate the safety of TIVc or TIV vaccine in children 3 to < 18 years of age who are at risk of complications of influenza disease due to underlying diseases.
- Trial name
- NCT01998477
- Testing
- TIVc, TIV
- Where
- 16 sites in Italy, Spain
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza A Virus, H1N1 Subtype
Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days
The purpose of this study is to compare the safety and tolerability of Zanamivir using a Rotahaler device presentation to placebo within the Rotahaler presentation and to the Diskhaler device.
- Trial name
- NAI113625 (NCT00989404)
- Testing
- Zanamivir
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Relenza® Sentinel Site Monitoring Program in Japan
To collect background information of patients receiving a prescription for Relenza® and study risk factors etc. for adverse drug reactions collected through spontaneous reporting.
- Trial name
- SSMP (NCT01199744)
- Testing
- zanamivir
- Volunteers
- 1,575 people
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA).
- Trial name
- NCT05045144
- Testing
- RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 1,586 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection
This open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (Tamiflu) in immunocompromised children, less than (<) 13 years of age, with confirmed…
- Trial name
- NCT01715909
- Testing
- Oseltamivir
- Where
- 50 sites in United States, Belgium and 13 more
- Volunteers
- 20 people
- Sponsor
- Hoffmann-La Roche
Influenza, Swine-origin A/H1N1 Influenza
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: To describe the immunogenicity of the candidate vaccines after a single injection.
- Trial name
- NCT00952276
- Testing
- Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
- Where
- 15 sites in United States
- Volunteers
- 548 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza Disease
Safety and Immunogenicity of a Inactivated Influenza Vaccine When Administered to Non Elderly Adults and Elderly Subjects.
The purpose of this study is to evaluate safety and immunogenicity of a single intramuscular (IM) injection of a Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2005-2006, when Administered to Non-Elderly Adults and…
- Trial name
- NCT00316615
- Testing
- influenza vaccine
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Novartis
Influenza, Human
Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents
The purpose of this study is to evaluate the immunogenicity and safety of 'IL-YANG Quadrivalent Seasonal Influenza Vaccine' in healthy Korean children and adolescents.
- Trial name
- NCT03445468
- Testing
- IL-YANG Quadrivalent Influenza Vaccine, IL-YANG Flu Vaccine Pre-filled Syringe
- Where
- South Korea
- Volunteers
- 379 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Relapsing Multiple Sclerosis
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
To assess whether participants treated with ofatumumab 20 mg subcutaneous (s.c.) administered once every 4 weeks (q4) can mount an adequate immune response to inactivated influenza vaccine as measured by humoral responses…
- Trial name
- NCT04667117
- Testing
- Quadrivalent influenza vaccine, Ofatumumab, iDMT
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Influenza
Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects
This clinical study will assess the safety, tolerability and immunogenicity of VAL-506440 in healthy adult subjects.
- Trial name
- NCT03076385
- Testing
- VAL-506440
- Where
- Germany
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Respiratory Viral Illnesses: Influenza A/B, RSV, Adenovirus
Residual Sample Collection for Respiratory Viral Panel
Collect de-identified, residual samples to support a clinical trial. Samples may be prospectively or retrospectively collected. Overall Study Objective Obtain clinical performance data to characterize clinical performance of the…
- Trial name
- NCT02049918
- Where
- United States
- Volunteers
- 1,487 people
- Sponsor
- GenMark Diagnostics
Orthomyxoviridae Infection, Influenza
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
This study is designed to test lot consistency of three different manufacturing lots and to generate safety and immunogenicity data of the investigational vaccine administered via the ID route.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00772109
- Testing
- Influenza Virus Vaccine USP Trivalent Types A and B
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 4,292 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company